Cite
HARVARD Citation
van Bodegraven, A. et al. (2014). Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation. Gut. 63 (9), pp. 1424-1430. [Online].